- Home
- CMC vs MIRM Comparison
CMC vs MIRM Comparison
Compare CMC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMC | MIRM |
|---|---|---|
| Founded | 1915 | 2018 |
| Country | United States | United States |
| Employees | 12690 | 418 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.4B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CMC | MIRM |
|---|---|---|
| Price | $62.97 | $121.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $73.33 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.4M | 945.6K |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $7,918,430,000.00 | $19,138,000.00 |
| Revenue This Year | $18.81 | $26.22 |
| Revenue Next Year | $6.34 | $22.04 |
| P/E Ratio | $15.18 | ★ N/A |
| Revenue Growth | ★ 25.57 | N/A |
| 52 Week Low | $49.66 | $50.25 |
| 52 Week High | $84.87 | $130.00 |
Technical Indicators
Market Signals| Indicator | CMC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 60.48 |
| Support Level | $55.83 | $88.92 |
| Resistance Level | $72.41 | N/A |
| Average True Range (ATR) | 2.39 | 6.48 |
| MACD | -0.83 | 0.71 |
| Stochastic Oscillator | 20.03 | 68.21 |
Price Performance
Historical ComparisonAbout CMC Commercial Metals Company
Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.